|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007600,
umls-concept:C0334227,
umls-concept:C0376571,
umls-concept:C0441655,
umls-concept:C0596988,
umls-concept:C1140680,
umls-concept:C1280500,
umls-concept:C1514485,
umls-concept:C1515655,
umls-concept:C1519697,
umls-concept:C1522424,
umls-concept:C1706395,
umls-concept:C2347610
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2002-3-14
|
|
pubmed:abstractText |
In order to generate an in vitro mouse model for the study of human ovarian cancers, we compared the effects of a truncated Brca1 mutant expression on cellular phenotype with those of a full-length sense and antisense Brca1 expression in the ID-8 mouse epithelial ovarian cancer cell line. The examined cellular processes include proliferation, tumorigenicity in syngeneic mice in vivo and sensitivity/resistance to several cytotoxic drugs. We found that the expression of a spontaneous truncated Brca1 mutant in ID-8 cells which contain two endogenous wild-type Brca1 alleles led to a dominant-negative effect of Brca1, demonstrated by an increase in tumorigenicity in vivo and in chemosensitivity. Expression of a truncated Brca1 mutant in a mouse epithelial ovarian cancer cell line could thus provide a powerful in vitro model for the study of human BRCA1-related ovarian tumorigenesis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1019-6439
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
845-53
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11894135-Animals,
pubmed-meshheading:11894135-Antineoplastic Agents,
pubmed-meshheading:11894135-Apoptosis,
pubmed-meshheading:11894135-BRCA1 Protein,
pubmed-meshheading:11894135-Blotting, Western,
pubmed-meshheading:11894135-DNA, Neoplasm,
pubmed-meshheading:11894135-DNA Primers,
pubmed-meshheading:11894135-Drug Resistance,
pubmed-meshheading:11894135-Female,
pubmed-meshheading:11894135-Genes, Dominant,
pubmed-meshheading:11894135-Mice,
pubmed-meshheading:11894135-Mice, Inbred C57BL,
pubmed-meshheading:11894135-Mice, Transgenic,
pubmed-meshheading:11894135-Mutation,
pubmed-meshheading:11894135-Ovarian Neoplasms,
pubmed-meshheading:11894135-Polymerase Chain Reaction,
pubmed-meshheading:11894135-RNA, Neoplasm,
pubmed-meshheading:11894135-Transfection,
pubmed-meshheading:11894135-Tumor Cells, Cultured
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line.
|
|
pubmed:affiliation |
Laboratoire d'Oncologie Moleculaire, Centre Jean Perrin, BP 392, 63 011 Clermont-Ferrand Cedex 1, France.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
